Goelzer Investment Management Inc. Invests $1.59 Million in Masimo Co. (MASI)

Goelzer Investment Management Inc. bought a new stake in Masimo Co. (NASDAQ:MASI) during the 1st quarter, HoldingsChannel reports. The fund bought 11,500 shares of the medical equipment provider’s stock, valued at approximately $1,590,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MASI. Vanguard Group Inc raised its position in shares of Masimo by 2.7% during the 3rd quarter. Vanguard Group Inc now owns 4,147,708 shares of the medical equipment provider’s stock worth $516,556,000 after purchasing an additional 109,065 shares during the last quarter. FMR LLC increased its holdings in shares of Masimo by 17.8% during the 4th quarter. FMR LLC now owns 3,889,562 shares of the medical equipment provider’s stock worth $417,622,000 after buying an additional 587,587 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd increased its holdings in shares of Masimo by 12.6% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 779,500 shares of the medical equipment provider’s stock worth $83,694,000 after buying an additional 87,476 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Masimo by 13.3% during the 4th quarter. Victory Capital Management Inc. now owns 726,329 shares of the medical equipment provider’s stock worth $77,986,000 after buying an additional 85,255 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Masimo by 11.7% during the 1st quarter. Janus Henderson Group PLC now owns 590,599 shares of the medical equipment provider’s stock worth $81,668,000 after buying an additional 61,762 shares during the last quarter. 83.16% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Jon Coleman sold 2,000 shares of the stock in a transaction on Monday, February 25th. The shares were sold at an average price of $130.00, for a total value of $260,000.00. Following the completion of the sale, the insider now owns 13,201 shares of the company’s stock, valued at $1,716,130. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven Barker sold 5,877 shares of the stock in a transaction on Monday, February 25th. The stock was sold at an average price of $130.00, for a total transaction of $764,010.00. Following the completion of the sale, the director now directly owns 70,709 shares of the company’s stock, valued at approximately $9,192,170. The disclosure for this sale can be found here. Insiders have sold 33,722 shares of company stock valued at $4,582,310 in the last ninety days. 11.50% of the stock is currently owned by company insiders.

A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Masimo from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $139.00 price objective on shares of Masimo in a research report on Friday, February 1st. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Piper Jaffray Companies increased their price objective on shares of Masimo from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Finally, UBS Group increased their price objective on shares of Masimo from $147.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $149.75.

Shares of MASI stock opened at $140.03 on Monday. Masimo Co. has a 52 week low of $95.53 and a 52 week high of $143.10. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 46.21, a price-to-earnings-growth ratio of 2.80 and a beta of 1.12.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.04. The firm had revenue of $231.70 million for the quarter, compared to the consensus estimate of $223.67 million. Masimo had a net margin of 22.49% and a return on equity of 18.61%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. As a group, equities research analysts forecast that Masimo Co. will post 3.12 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Goelzer Investment Management Inc. Invests $1.59 Million in Masimo Co. (MASI)” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/13/goelzer-investment-management-inc-invests-1-59-million-in-masimo-co-masi.html.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: Blockchain

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.